KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Interest & Investment Income (2018 - 2025)

Adaptive Biotechnologies' Interest & Investment Income history spans 8 years, with the latest figure at $2.4 million for Q2 2025.

  • For Q2 2025, Interest & Investment Income fell 36.51% year-over-year to $2.4 million; the TTM value through Jun 2025 reached $11.6 million, down 31.2%, while the annual FY2025 figure was $9.4 million, 35.02% down from the prior year.
  • Interest & Investment Income for Q2 2025 was $2.4 million at Adaptive Biotechnologies, down from $2.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.6 million in Q4 2023 and bottomed at $239000.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is $2.6 million (2022), against an average of $2.3 million.
  • The largest annual shift saw Interest & Investment Income plummeted 77.95% in 2021 before it skyrocketed 1015.87% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $239000.0 in 2021, then skyrocketed by 988.7% to $2.6 million in 2022, then soared by 77.29% to $4.6 million in 2023, then crashed by 33.41% to $3.1 million in 2024, then fell by 22.17% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Interest & Investment Income are $2.4 million (Q2 2025), $2.7 million (Q1 2025), and $3.1 million (Q4 2024).